Hangzhou Tigermed Consulting Co., Ltd. (HNGZY)
USD 4.0
(0.0%)
USD 4.0
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 7.38 Billion USD | -0.95% |
| 2022 | 1.05 Billion USD | 30.17% |
| 2021 | 808.38 Million USD | 74.79% |
| 2020 | 462.49 Million USD | 14.0% |
| 2019 | 405.69 Million USD | -82.37% |
| 2018 | 2.3 Billion CNY | 36.37% |
| 2017 | 1.68 Billion CNY | 43.63% |
| 2016 | 1.17 Billion CNY | 22.73% |
| 2015 | 956.99 Million CNY | 53.23% |
| 2014 | 624.56 Million CNY | 85.59% |
| 2013 | 336.51 Million CNY | 32.32% |
| 2012 | 254.31 Million CNY | 31.59% |
| 2011 | 193.26 Million CNY | 57.32% |
| 2010 | 122.84 Million CNY | 95.63% |
| 2009 | 62.79 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 1.7 Billion CNY | 1.07% |
| 2024 Q1 | 1.66 Billion CNY | -4.32% |
| 2024 Q2 | 1.69 Billion CNY | 2.34% |
| 2023 Q2 | 1.9 Billion CNY | 625.52% |
| 2023 FY | 1.04 Billion USD | -0.95% |
| 2023 Q1 | 262.74 Million USD | 11.95% |
| 2023 Q4 | 1.73 Billion CNY | -10.62% |
| 2023 Q3 | 1.93 Billion CNY | 1.75% |
| 2022 Q3 | 263.6 Million USD | -85.16% |
| 2022 Q4 | 234.7 Million USD | -10.96% |
| 2022 Q2 | 1.77 Billion CNY | -2.09% |
| 2022 Q1 | 1.81 Billion CNY | 0.15% |
| 2022 FY | 1.05 Billion USD | 30.17% |
| 2021 Q2 | 177.63 Million CNY | 28.15% |
| 2021 FY | 808.38 Million USD | 74.79% |
| 2021 Q3 | 1.33 Billion CNY | 651.1% |
| 2021 Q4 | 1.81 Billion CNY | 35.79% |
| 2021 Q1 | 138.6 Million CNY | -84.46% |
| 2020 Q2 | 801.88 Million CNY | 23.35% |
| 2020 Q3 | 848.47 Million CNY | 5.81% |
| 2020 Q4 | 891.81 Million CNY | 5.11% |
| 2020 FY | 462.49 Million USD | 14.0% |
| 2020 Q1 | 650.1 Million CNY | -15.82% |
| 2019 Q3 | 693.7 Million CNY | -4.76% |
| 2019 Q4 | 772.31 Million CNY | 11.33% |
| 2019 FY | 405.69 Million USD | -82.37% |
| 2019 Q1 | 608.88 Million CNY | -13.78% |
| 2019 Q2 | 728.4 Million CNY | 19.63% |
| 2018 Q1 | 473.15 Million CNY | -7.6% |
| 2018 FY | 2.3 Billion CNY | 36.37% |
| 2018 Q3 | 561.67 Million CNY | 0.37% |
| 2018 Q4 | 706.21 Million CNY | 25.73% |
| 2018 Q2 | 559.61 Million CNY | 18.27% |
| 2017 Q3 | 431.75 Million CNY | 11.32% |
| 2017 FY | 1.68 Billion CNY | 43.63% |
| 2017 Q4 | 512.08 Million CNY | 18.61% |
| 2017 Q2 | 387.86 Million CNY | 9.15% |
| 2017 Q1 | 355.33 Million CNY | 9.3% |
| 2016 Q1 | 274.49 Million CNY | -8.64% |
| 2016 Q2 | 291.27 Million CNY | 6.11% |
| 2016 FY | 1.17 Billion CNY | 22.73% |
| 2016 Q4 | 325.09 Million CNY | 14.6% |
| 2016 Q3 | 283.67 Million CNY | -2.61% |
| 2015 Q2 | 210.76 Million CNY | -2.56% |
| 2015 Q3 | 229.49 Million CNY | 8.89% |
| 2015 Q4 | 300.44 Million CNY | 30.92% |
| 2015 Q1 | 216.3 Million CNY | 5.17% |
| 2015 FY | 956.99 Million CNY | 53.23% |
| 2014 Q2 | 115.26 Million CNY | -0.33% |
| 2014 Q1 | 115.64 Million CNY | 27.52% |
| 2014 FY | 624.56 Million CNY | 85.59% |
| 2014 Q4 | 205.66 Million CNY | 9.41% |
| 2014 Q3 | 187.98 Million CNY | 63.08% |
| 2013 FY | 336.51 Million CNY | 32.32% |
| 2013 Q1 | 74.97 Million CNY | 9.41% |
| 2013 Q3 | 79.49 Million CNY | -12.98% |
| 2013 Q4 | 90.69 Million CNY | 14.09% |
| 2013 Q2 | 91.35 Million CNY | 21.85% |
| 2012 Q1 | 56.4 Million CNY | 10.61% |
| 2012 Q3 | 63.74 Million CNY | -2.9% |
| 2012 Q4 | 68.52 Million CNY | 7.51% |
| 2012 FY | 254.31 Million CNY | 31.59% |
| 2012 Q2 | 65.64 Million CNY | 16.39% |
| 2011 Q3 | 48.7 Million CNY | 0.0% |
| 2011 Q4 | 50.99 Million CNY | 4.69% |
| 2011 FY | 193.26 Million CNY | 57.32% |
| 2010 FY | 122.84 Million CNY | 95.63% |
| 2009 FY | 62.79 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| American Bio Medica Corporation | 913 Thousand USD | -808666.644% |
| Arrayit Corporation | 4.37 Million USD | -168589.362% |
| Atlantic International Corp. | - USD | -Infinity% |
| Biocept, Inc. | 25.85 Million USD | -28456.112% |
| Bioqual, Inc. | 58.59 Million USD | -12502.696% |
| CardioGenics Holdings Inc | - USD | -Infinity% |
| DermTech, Inc. | 15.29 Million USD | -48174.317% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| HTG Molecular Diagnostics, Inc. | 6.36 Million USD | -115887.815% |
| iMD Companies, Inc. | - USD | -Infinity% |
| IDenta Corp. | 1.05 Million USD | -702078.554% |
| Interpace Biosciences, Inc. | 40.21 Million USD | -18261.863% |
| Integrative Health Technologies, Inc. | 447.49 Thousand USD | -1649968.371% |
| InVitro International | 792.62 Thousand USD | -931489.53% |
| Lumos Diagnostics Holdings Limited | 11.13 Million USD | -66237.611% |
| Many Bright Ideas Technologies Inc. | - USD | -Infinity% |
| Medical Imaging Corp. | 7.22 Million USD | -102112.188% |
| NovelStem International Corp. | 12 Thousand USD | -61533562.167% |
| Optigenex Inc. | 465.97 Thousand USD | -1584559.841% |
| PharmChem, Inc. | 6.01 Million USD | -122713.448% |
| Proteome Sciences plc | 6.4 Million USD | -115264.008% |
| Response Genetics, Inc | 18.04 Million USD | -40831.483% |
| Rennova Health, Inc. | 13.03 Million USD | -56542.697% |
| RushNet, Inc. | 1.78 Million USD | -412905.317% |
| ScreenPro Security Inc. | 1.91 Million USD | -385670.226% |
| Stella Diagnostics Inc. | - USD | -Infinity% |
| StageZero Life Sciences Ltd. | 3.79 Million USD | -194468.948% |
| Todos Medical Ltd. | 7.69 Million USD | -95858.927% |